28 research outputs found
Borderline Brenner tumor of the ovary: A case report with immunohistochemical and molecular study
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
Pancreatic ductal adenocarcinoma (PDAC) represents an unmet clinical need due to the very poor
prognosis and the lack of effective therapy. Here we investigated the potential of domatinostat (4SC-202), a new class
I histone deacetylase (HDAC) inhibitor, currently in clinical development, to sensitize PDAC to first line standard gemcitabine
(G)/taxol (T) doublet chemotherapy treatment.
Methods: Synergistic anti-tumor effect of the combined treatment was assessed in PANC1, ASPC1 and PANC28
PDAC cell lines in vitro as well as on tumor spheroids and microtissues, by evaluating combination index (CI), apoptosis,
clonogenic capability. The data were confirmed in vivo xenograft models of PANC28 and PANC1 cells in athymic
mice. Cancer stem cells (CSC) targeting was studied by mRNA and protein expression of CSC markers, by limiting
dilution assay, and by flow cytometric and immunofluorescent evaluation of CSC mitochondrial and cellular oxidative
stress. Mechanistic role of forkhead box M1 (FOXM1) and downstream targets was evaluated in FOXM1-overexpressing
PDAC cells.
Results: We showed that domatinostat sensitized in vitro and in vivo models of PDAC to chemotherapeutics commonly
used in PDAC patients management and particularly to GT doublet, by targeting CSC compartment through
the induction of mitochondrial and cellular oxidative stress. Mechanistically, we showed that domatinostat hampers
the expression and function of FOXM1, a transcription factor playing a crucial role in stemness, oxidative stress modulation
and DNA repair. Domatinostat reduced FOXM1 protein levels by downregulating mRNA expression and inducing
proteasome-mediated protein degradation thus preventing nuclear translocation correlated with a reduction of
FOXM1 target genes. Furthermore, by overexpressing FOXM1 in PDAC cells we significantly reduced domatinostatinducing
oxidative mitochondrial and cellular stress and abolished GT sensitization, both in adherent and spheroid
cells, confirming FOXM1 crucial role in the mechanisms described. Finally, we found a correlation of FOXM1 expression
with poor progression free survival in PDAC chemotherapy-treated patients
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a
devastating malignancy with a poor prognosis. The combination of cisplatin (CDDP) plus
cetuximab (CX) is one of the standard first-line treatments in this disease. However, this
therapeutic regimen is often associated with high toxicity and resistance, suggesting that
new combinatorial strategies are needed to improve its therapeutic index. In our study,
we evaluated the antitumor effects of valproic acid (VPA), a well-known antiepileptic
agent with histone deacetylase inhibitory activity, in combination with CDDP/CX doublet
in head and neck squamous cell carcinoma (HNSCC) models. We demonstrated, in
HNSCC cell lines, but not in normal human fibroblasts, that simultaneous exposure to
equitoxic doses of VPA plus CDDP/CX resulted in a clear synergistic antiproliferative and
pro-apoptotic effects. The synergistic antitumor effect was confirmed in four different
3D-self-assembled spheroid models, suggesting the ability of the combined approach
to affect also the cancer stem cells compartment. Mechanistically, VPA enhanced
DNA damage in combination treatment by reducing the mRNA expression of ERCC
Excision Repair 1, a critical player in DNA repair, and by increasing CDDP intracellular
concentration via upregulation at transcriptional level of CDDP influx channel copper
transporter 1 and downregulation of the ATPAse ATP7B involved in CDDP-export.
Valproic acid also induced a dose-dependent downregulation of epidermal growth factor
receptor (EGFR) expression and of MAPK and AKT downstream signaling pathways
and prevent CDDP- and/or CX-induced EGFR nuclear translocation, a well-known
mechanism of resistance to chemotherapy. Indeed, VPA impaired the transcription
of genes induced by non-canonical activity of nuclear EGFR, such as cyclin D1 and thymidylate synthase. Finally, we confirmed the synergistic antitumor effect also
in vivo in both heterotopic and orthotopic models, demonstrating that the combined
treatment completely blocked HNSCC xenograft tumors growth in nude mice. Overall,
the introduction of a safe and generic drug such as VPA into the conventional treatment
for R/M HNSCC represents an innovative and feasible antitumor strategy that warrants
further clinical evaluation. A phase II clinical trial exploring the combination of VPA and
CDDP/CX in R/M HNSCC patients is currently ongoing in our institute
Paralogous HOX13 Genes in Human Cancers
Hox genes (HOX in humans), an evolutionary preserved gene family, are key determinants of embryonic development and cell memory gene program. Hox genes are organized in four clusters on four chromosomal loci aligned in 13 paralogous groups based on sequence homology (Hox gene network). During development Hox genes are transcribed, according to the rule of “spatio-temporal collinearity”, with early regulators of anterior body regions located at the 3’ end of each Hox cluster and the later regulators of posterior body regions placed at the distal 5’ end. The onset of 3’ Hox gene activation is determined by Wingless-type MMTV integration site family (Wnt) signaling, whereas 5’ Hox activation is due to paralogous group 13 genes, which act as posterior-inhibitors of more anterior Hox proteins (posterior prevalence). Deregulation of HOX genes is associated with developmental abnormalities and different human diseases. Paralogous HOX13 genes (HOX A13, HOX B13, HOX C13 and HOX D13) also play a relevant role in tumor development and progression. In this review, we will discuss the role of paralogous HOX13 genes regarding their regulatory mechanisms during carcinogenesis and tumor progression and their use as biomarkers for cancer diagnosis and treatment
Duodenal epithelioid angiosarcoma: immunohistochemical and clinical findings. A case report
Massive edema of ovary with cytogenetic alteration of chromosome 12q13-15 in adolescent patient: A case report
BACKGROUND: The massive edema of ovary, with or without fibromatosis, is a rare tumor-like entity characterized by an increase in volume of one or both ovaries for accumulation of edema fluid in the stroma that separates the follicular structures. CASE: We report a rare case, very peculiar also for its association with a massive stromal fibromatosis and for the presence, never described, of tumoral areas with CHOP gene translocation, on chromosome 12q13–15
Coexistence of Granular Cell Tumor and Invasive Ductal Breast Cancer in Contralateral Breasts: A Case Report
Granular cell tumor (GCT) is a benign tumor of the breast that can mimic, on breast imaging, invasive carcinomas. Biological evolution of mammary GCT is unknown, especially if it is associated with an invasive carcinoma in the same or contralateral breast. This report details the morphological features of these synchronous lesions highlighting their biological characteristics and suggesting an appropriate follow up
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
Triple Negative Breast Cancers (TNBC) subtype is an aggressive disease with poor clinical outcome. The only treatment available is surgery followed by chemotherapy or radiotherapy. Programmed death-ligand 1 (PD-L1) is a trans-membrane protein expressed on a wide variety of cells including immune cells, epithelial and vascular endothelial cells. Recently, PD-1/PD-L1 pathway signaling was described as an adaptive immune resistance mechanism enacted by the tumor cells to evade the immune response. Its presence on tumor cell membranes, acquired for this reason, through time, is an important prognostic value. However, data available in the literature about PD-L1 immunohistochemical expression in breast cancer are often discordant and not uniform, probably for the use of different antibodies clones and the high molecular heterogeneity of the different tumor types. The absence of target therapies, in particular for TNBC, has shifted the clinical attention mainly on the role of PD-L1 in this subtype of breast cancer. In this study, we evaluated tumor and TIL (tumor infiltrating lymphocytes) PDL-1 expression in a series of TNBC, included in Tissue Micro Arrays (TMAs), to define its real prognostic value, optimizing immunohistochemistry method with an “approved for diagnostic assay” antibody. PD-L1 expression directly correlated with proliferation index (Ki-67), glycemia, the presence of diabetes and indirectly with menopausal status, presence of lymph node metastasis and relapse. The analysis of Kaplan–Meier showed that an increased PD-L1 expression was strongly associated with better disease-free survival (DFS) but not correlated with overall survival (OS). Our data confirmed that PD-L1 could be an important marker for prognostic stratification and for planning immune checkpoint inhibitors therapies in patients with TNBC